The American Journal of Managed Care17h
FDA Approves Isatuximab With VRd as First-Line Option for Transplant-Ineligible Multiple Myeloma
Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...
oncnursingnews18h
FDA Approves Isatuximab Plus VRd for Newly Diagnosed Myeloma
The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...
Targeted Oncology18h
FDA Approves Isatuximab Plus VRd in Transplant-Ineligible Multiple Myeloma
The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...
Cure Today1d
FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible Multiple Myeloma
The Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) with Velcade (bortezomib), Revlimid ...
Targeted Oncology3d
Positive Isa-VRd Trials in Transplant-Ineligible Myeloma Show New Approach
During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for ...
Pharmabiz15d
ALX Oncology doses first patients for UMBRELLA phase 1/2 study with Sanofi to evaluate evorpacept in combination with Sarclisa
South San Franciso, California Friday, September 6, 2024, 16:30 Hrs [IST] ...
Medscape15d
Serum Free Light Chain Measurement Aids the Diagnosis of Myeloma in Patients With Severe Renal Failure
Background: Monoclonal free light chains (FLCs) frequently cause rapidly progressive renal failure in patients with multiple myeloma. Immunoassays which provide quantitative measurement of FLCs in ...
Nasdaq17d
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
The Company’s pipeline of therapeutic candidates with standard-of-care agents include: About SARCLISASARCLISA (isatuximab-irfc) is a monoclonal antibody that binds to a specific epitope on the ...
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal ...
Seeking Alpha17d
Sanofi: A Long-Term Cash Cow With High Dividends
Since my last article, Sanofi’s stock price has continued to rise, thanks in part to strong sales of its immunology and oncology franchises. For example, Dupixent sales were €3.03 billion for ...